Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer
CDK4/6 inhibitors in combination with endocrine therapy are widely used to treat HR+/HER2− metastatic breast cancer leading to improved progressi…
